Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo

HER2/neu gene amplification and PIK3CA driver mutations are common in uterine serous carcinoma (USC), and may represent ideal therapeutic targets against this aggressive variant of endometrial cancer. We examined the sensitivity to neratinib, taselisib and the combination of the two compounds in in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Ther
Auteurs principaux: Lopez, Salvatore, Cocco, Emiliano, Black, Jonathan, Bellone, Stefania, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Schwab, Carlton L., English, Diana P., Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Terranova, Corrado, Angioli, Roberto, Santin, Alessandro D.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4636465/
https://ncbi.nlm.nih.gov/pubmed/26333383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0383
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires